Patents by Inventor Georges Leclercq

Georges Leclercq has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACCELERATED HUMAN HEMATOPOEITIC STEM CELL DIFFERENTIATION TOWARDS MATURE NATURAL KILLER CELLS WITH ENHANCED ANTIBODY-DEPENDENT CYTOTOXIC ACTIVITY
    Publication number: 20220025327
    Abstract: The present invention in general relates to a method of differentiating human hematopoietic stem cells (HSC) into mature natural killer (NK) cells; wherein said method is in particular characterized in that mature NK cells are obtainable very early during the differentiation method, and that these NK cells display increased CD16 expression and antibody-dependent cellular cytotoxicity (ADCC) (FIG. 11). The method of the invention specifically encompasses transfecting and/or transducing HSCs with at least one transcription factor selected from T-Box expressed in T cells (T-BET) and Eomesodermin (EOMES); or a combination thereof.
    Type: Application
    Filed: September 30, 2019
    Publication date: January 27, 2022
    Applicant: Universiteit Gent
    Inventors: Laura Kiekens, Georges Leclercq
  • Antibodies to Ly49E and CD94/NKG2 receptors
    Publication number: 20030095965
    Abstract: The present invention relates to monoclonal antibodies to the Ly49E and Ly49C receptors and to monoclonal antibodies to the CD94/NKG2A, CD94/NKG2C and/or CD94/NKG2E receptors, and to uses thereof in preventing, alleviating and/or treating diseases associated with transplantation (organ/bone marrow) or with autoimmunity.
    Type: Application
    Filed: May 2, 2002
    Publication date: May 22, 2003
    Inventors: Katrien Van Beneden, Jozef De Boever, Georges Leclercq